Department of Urogynaecology, Kingston Hospital, Kingston upon Thames, London.
Neurourol Urodyn. 2019 Mar;38(3):887-892. doi: 10.1002/nau.23924. Epub 2019 Feb 22.
Urethral bulking agents (UBAs) to treat stress urinary incontinence was first described in the 1930s, when paraffin was used to increase urethral resistance. Since then, several agents have been introduced to the market, with varying degrees of safety, efficacy, and durability. The agents currently available include calcium hydroxyl apatite (Coaptite®), carbon coated zirconium (Durasphere®); polydimethylsiloxane elastomer (Macroplastique®); and polyacrylamide hydrogel (Bulkamid®). The latest product, PDMS-U (Urolastic ®) is a silicone gel that polymerizes when injected. The short term efficacy of UBAs are generally encouraging; however, longer follow up results show the success rates are reduced and many women will require a repeat treatment. This review looks at the currently available UBAs, application techniques, and the clinical data on their safety and efficacy.
尿道填充剂（UBAs）用于治疗压力性尿失禁的方法最早在 20 世纪 30 年代提出，当时使用石蜡来增加尿道阻力。此后，已经有几种制剂上市，其安全性、疗效和持久性各有不同。目前可用的制剂包括羟磷灰石钙（Coaptite®）、碳化锆（Durasphere®）、聚二甲基硅氧烷弹性体（Macroplastique®）和聚丙烯酰胺水凝胶（Bulkamid®）。最新产品 PDMS-U（Urolastic ®）是一种注射后聚合的硅胶。UBAs 的短期疗效通常令人鼓舞；然而，更长时间的随访结果显示，成功率降低，许多女性需要重复治疗。本文综述了目前可用的 UBAs、应用技术以及关于其安全性和疗效的临床数据。
